Literature DB >> 23991913

Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern.

A M Su1, W Shih, A P Presson, L Chang.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) with mixed bowel habits (IBS-M) is a heterogeneous subtype with varying symptoms of constipation and diarrhea, and has not been well characterized. We aimed to characterize gastrointestinal (GI) and non-GI symptoms in IBS-M patients from a US patient population, and to compare them with IBS with constipation (IBS-C) and diarrhea (IBS-D).
METHODS: Subjects answering community advertisements and meeting Rome III criteria for IBS completed symptom questionnaires. KEY
RESULTS: Of the initial 289 IBS patients identified, one third (n = 51, 32.5%) who met Rome III criteria for IBS-M endorsed having either loose stools or hard stools due to medication. These patients had more severe symptoms and longer duration of flares compared to the rest of the IBS-M group (p = 0.014, p = 0.005). Excluding IBS-M patients with medication-related extremes in stool form who could not be reclassified by medical history, 247 IBS patients were assessed. IBS-M was the most common (44.1%), followed by IBS-C (27.9%), IBS-D (26.3%), and IBS-U (unsubtyped, 1.6%). While IBS-M shared symptoms with both IBS-C and IBS-D, there were significant differences in the prevalence of bowel habit symptoms (p-value range: <0.001-0.002). IBS-M patients reported most bothersome symptoms that were more similar to IBS-D, with the most common being irregular bowel habits (27.5%), bloating (26.6%), and abdominal pain (20.2%). There were no differences in non-GI symptoms between subtypes. CONCLUSIONS & INFERENCES: IBS-M is a heterogeneous symptom group and thus requires that subclassification criteria be better defined. Use of laxative/antidiarrheal medications adds to the diagnostic complexity in a potentially more severe subset of IBS-M and should be assessed for accurate subclassification.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  abdominal pain; constipation; diarrhea; irritable bowel syndrome; mixed bowel habits

Mesh:

Year:  2013        PMID: 23991913      PMCID: PMC3865067          DOI: 10.1111/nmo.12220

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  32 in total

1.  IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment.

Authors:  Olafur S Palsson; Jeffrey S Baggish; Marsha J Turner; William E Whitehead
Journal:  Am J Gastroenterol       Date:  2011-11-08       Impact factor: 10.864

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator.

Authors:  Douglas A Drossman; Carolyn B Morris; Yuming Hu; Brenda B Toner; Nicholas Diamant; Jane Leserman; Michael Shetzline; Christine Dalton; Shrikant I Bangdiwala
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

4.  [Prevalence and clinical characteristics of the IBS subtypes according to the Rome III criteria in patients from a clinical, multicentric trial. A report from the Mexican IBS Working Group].

Authors:  M Schmulson; J A Vargas; A López-Colombo; J M Remes-Troche; J C López-Alvarenga
Journal:  Rev Gastroenterol Mex       Date:  2010 Oct-Dec

5.  Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome.

Authors:  T Lembo; B Naliboff; J Munakata; S Fullerton; L Saba; S Tung; M Schmulson; E A Mayer
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

6.  Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar.

Authors:  Spencer D Dorn; Carolyn B Morris; Yuming Hu; Brenda B Toner; Nicholas Diamant; William E Whitehead; Shrikant I Bangdiwala; Douglas A Drossman
Journal:  J Clin Gastroenterol       Date:  2009-03       Impact factor: 3.062

7.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

8.  The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale.

Authors:  J S Labus; R Bolus; L Chang; I Wiklund; J Naesdal; E A Mayer; B D Naliboff
Journal:  Aliment Pharmacol Ther       Date:  2004-07-01       Impact factor: 8.171

9.  Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype.

Authors:  Fermín Mearin; Agustín Balboa; Xavier Badía; Eva Baró; Ellen Caldwell; Mercedes Cucala; Manuel Díaz-Rubio; Arturo Fueyo; Julio Ponce; Montse Roset; Nicholas J Talley
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-02       Impact factor: 2.566

10.  Evidence for the ambiguity of the term constipation: the role of irritable bowel syndrome.

Authors:  C S Probert; P M Emmett; H A Cripps; K W Heaton
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

View more
  16 in total

1.  Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response.

Authors:  Alexa Orand; Bruce Naliboff; Malin Gadd; Wendy Shih; Tiffany Ju; Angela P Presson; Emeran A Mayer; Lin Chang
Journal:  Psychoneuroendocrinology       Date:  2016-07-19       Impact factor: 4.905

2.  Response of irritable bowel syndrome with constipation patients administered a combined quebracho/conker tree/M. balsamea Willd extract.

Authors:  Kenneth Brown; Brandi Scott-Hoy; Linda W Jennings
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

3.  Using the Rome IV Criteria to Help Manage the Complex IBS Patient.

Authors:  Lisa D Lin; Lin Chang
Journal:  Am J Gastroenterol       Date:  2017-12-19       Impact factor: 10.864

Review 4.  Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.

Authors:  Susan Lucak; Lin Chang; Albena Halpert; Lucinda A Harris
Journal:  Therap Adv Gastroenterol       Date:  2016-09-16       Impact factor: 4.409

Review 5.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

Review 6.  Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome.

Authors:  Maria M Buckley; Siobhain M O'Mahony; Dervla O'Malley
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

7.  Shugan-decoction relieves visceral hyperalgesia and reduces TRPV1 and SP colon expression.

Authors:  Jing-Juan Shang; Jian-Ye Yuan; Hui Xu; Rong-Zhu Tang; Yue-Bin Dong; Jian-Qun Xie
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 8.  Alternative Treatments for Minor GI Ailments.

Authors:  A K Mohiuddin
Journal:  Innov Pharm       Date:  2019-07-05

9.  Catecholaminergic Gene Polymorphisms Are Associated with GI Symptoms and Morphological Brain Changes in Irritable Bowel Syndrome.

Authors:  Alexa Orand; Arpana Gupta; Wendy Shih; Angela P Presson; Christian Hammer; Beate Niesler; Nuwanthi Heendeniya; Emeran A Mayer; Lin Chang
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

Review 10.  Abdominal bloating: pathophysiology and treatment.

Authors:  A Young Seo; Nayoung Kim; Dong Hyun Oh
Journal:  J Neurogastroenterol Motil       Date:  2013-10-07       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.